What impact could the latest 2017 hypertension guidelines have on your patients? Click through our quick slideshow to find out.
First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial
Lipocene anticipates the phase 3 trial data will support an NDA submission for LPCN 1154 to treat PPD in mid-2026, the company said.
The Weekly Dose: Cannabis, Contraceptives, and Advances in Alzheimer Disease and Gonorrhea Treatment
Clinical insights on cannabis and dementia, hormonal contraceptives and postpartum depression, the FDA-approved blood test for Alzheimer disease, more.
Reconstituted ACIP Votes Yes on Clesrovimab for Infants and Flu Shot For All, But Thimerosal Has Got to Go
The new, 7-member committee was clear on its support for the mAb for infants and the essential role of vaccination against influenza but wants an alternative preservative to thimerosal.
The Weekly Dose: Advancements in Colonoscopy, AI for Mammography, and Telemedicine Antibiotic Stewardship
Discover the latest breakthroughs in clinical research, from at-home cancer screening to AI advancements in mammography, shaping future healthcare practices.
Only Half of Patients Adherent to Antidementia Medication Regimens at 1 Year: New Meta-Analysis Results
Suboptimal adherence with antidementia drugs is associated with poorer clinical outcomes including accelerated disease progression and symptomatology.
Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial
ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.